Lantern Pharma Reports Breakthrough in DLBCL Treatment with AI-Developed Drug LP-284

Lantern Pharma (NASDAQ: LTRN) has achieved a significant milestone in the treatment of aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL) with its drug candidate LP-284. A patient participating in the ongoing Phase 1 trial exhibited a complete metabolic response after just two cycles of treatment, a first for LP-284. This development is particularly noteworthy as the patient had previously not responded to three other treatments, including CAR-T and bispecific antibody therapy.

The success of LP-284, developed using Lantern Pharma's proprietary RADR(R) AI platform, highlights the drug's potential as a breakthrough therapy for refractory lymphomas. The synthetic lethal mechanism of LP-284 offers new hope for patients with limited treatment options, positioning Lantern Pharma as a significant contributor to the $4 billion global B-cell cancer market. For more details on this groundbreaking development, visit https://ibn.fm/TCGHH.

This achievement not only accelerates the development timeline for LP-284 but also serves as a validation of the efficacy of AI-driven approaches in oncology drug development. Lantern Pharma's RADR(R) platform has demonstrated its capability to rapidly advance from initial insights to clinical trials, showcasing the transformative potential of AI in identifying and developing novel cancer therapies. The complete metabolic response observed in the Phase 1 trial participant underscores the promise of LP-284 and similar AI-developed drugs in addressing unmet medical needs in oncology.